Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Recruiting 38Active not recruiting 15Not yet recruiting 9Suspended 4Withdrawn 3Completed 3Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Classical hematology 1

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1

Interventions

venetoclax 7Azacitidine 5Specimen Handling 4fludarabine phosphate 3Tacrolimus 2Mitoxantrone 2Melphalan 2Cyclophosphamide 2Biopsy 2vactosertib 1regorafenib 1methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside Pt(II) 1iadademstat 1gilteritinib 1fludarabine 1decitabine and cedazuridine drug combination 1beta-apocarotenoid-14',13'-dioxygenase 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1TAK-243 1Stem Cell Transplantation 1Radiotherapy, Intensity-Modulated 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Interleukin-2 1Idarubicin 1IL32 protein, human 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Leukemia, Myeloid, Acute × Specimen Handling × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06514261 2026-05-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

National Cancer Institute (NCI)

Phase 1 Suspended
45 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06802523 2026-05-13

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Suspended
53 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡